Tags : sx3


Tobias F. Rohner new partner at VISCHER

Tobias F. Rohner has joined VISCHER as a partner on 1 February 2023 strengthening the tax team. As a partner in the Zurich office he is co-head of the tax team. With more than 20 years of experience as a tax lawyer, Rohner has excellent expertise in advising international and domestic companies, start-ups, fund and […]

Banking & Finance

VISCHER advises Oberland Capital on its agreement with Helsinn

As we have informed here, the Helsinn Group has closed a financing agreement with Oberland Capital Management. In this sense, VISCHER has advised Oberland Capital Management on its financing agreement with the Ticino based group. Oberland Capital is a private investment firm with assets under management in excess of USD 3 bn, focused exclusively on investing […]

Banking & Finance

Homburger advises Raiffeisen on the incorporation of 6 branches as

Homburger has advised Raiffeisen Schweiz Genossenschaft on all legal, regulatory and tax aspects of the spin-off of its 6 branches into independent Raiffeisen banks. The team was led by René Bösch (financial market regulation) and included Benjamin Leisinger (financial market regulation, pictured), Dieter Grünblatt (tax), Andrea Widmer Grimm (corporate), Peter Müller (tax), Laura Müller and […]

Corporate Tax

VISCHER advises Invision with CHF 145m continuation fund

As we have informed here, Invision, a renowned investment company focusing on succession solutions and growth financing for medium-sized companies in German-speaking countries, has launched and successfully closed Invision Logistics LP, a CHF 145m continuation fund for the further development of Schneider Group, an internationally oriented medium-sized forwarding company with more than 800 employees at […]

Banking & Finance

VISCHER advises Resistell with series B first tranche of CHF

Resistell, a leader in phenotypic nanomotion technology for measuring living cells, based in Muttenz, Switzerland, has taken another major step to achieving its vision by closing a first tranche of its series B financing round raising CHF 8.5million from new and existing investors. Investors include EIC Fund, TRUMPF Venture, OCCIDENT, Zürcher Kantonalbank, Launchpad, and private […]


Roland Böhi becomes partner of Bratschi in Zurich

Roland Böhi has joined Bratschi in Zurich as a partner from Prager Dreifuss on 1 January 2023. He is active in all areas of tax law and his long-standing expertise includes international tax law, m&a, private equity, financing, real estate, transfer pricing aspects as well as tax planning for private clients, including family offices. Böhi […]

Banking & Finance

Walder Wyss advises UBS with the financing in CSD Group

Walder Wyss has acted as counsel to UBS Switzerland as mandated lead arranger, underwriter, bookrunner, agent, security agent and original lender in connection with the financing of the acquisition of a majority stake in CSD Group by Initiative & Finance’s “Tomorrow” fund (I&F Tomorrow). CSD Group is one of Switzerland’s leading independent environmental engineering consultancies, […]


Altenburger strengthens its legal team

Isabelle Meyer and Laura Benhammou have joined Altenburger as senior associates. Isabelle Meyer (pictured left) is specialized in domestic and international litigation and she also has broad experience in internal and regulatory investigations, including anti-money laundering, and in white collar crime matters. Meyer works in the Dispute Resolution Team as well as the Banking, Finance […]


Robin Moser becomes equity partner of Loyens & Loeff

Robin Moser becomes Loyens & Loeff‘s fifth Swiss equity partner with effect from 1 January 2023. He joined Loyens & Loeff in 2019 and heads the Litigation and Risk Management department in the Zurich office. The law and tax firm has appointed a total of eleven new equity partners with effect from 1 January 2021. […]


Walder Wyss advises Pfizer on its investment in Anokion

As we have informed here last 10 November 2022, the clinical-stage biotechnology company Anokion has closed an USD 35 million equity investment from Pfizer through the Pfizer Breakthrough Growth Initiative. The Biotech company is focus on the treating autoimmune disease by restoring normal immune tolerance. Walder Wyss has also advised on the deal acting as […]